单唾液酸四己糖神经节苷脂联合阿托伐他汀治疗急性脑梗死的临床效果观察

Clinical effect of monosialotetrahexosyl ganglioside combined with atorvastatin on acute cerebral infarction

目的观察单唾液酸四己糖神经节苷脂(MG)联合阿托伐他汀治疗急性脑梗死(ACI)的临床效果。方法 ACI患者100例,随机分为观察组和对照组,每组50例,两组均给予常规治疗,对照组加阿托伐他汀治疗,观察组加MG联合阿托伐他汀治疗。观察两组治疗前后血清C反应蛋白(CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、神经元特异性烯醇化酶(NSE)、S100-β蛋白水平及美国国立卫生研究院卒中量表(NIHSS)评分、日常生活能力(ADL)量表评分及临床疗效。结果治疗后,观察组血清CRP、IL-6、TNF-α、NSE、S100-β蛋白水平及NIHSS评分均低于对照组(P<0.05),ADL评分高于对照组(P<0.05)。治疗有效率观察组为84.0%(42/50),对照组为62.0%(31/50),观察组疗效优于对照组(P<0.05)。结论MG联合阿托伐他汀治疗ACI,可抑制局部炎症反应,减轻脑损伤,效果优于单纯阿托伐他汀治疗。

Objective To observe the clinical effect of monosialotetrahexosyl ganglioside combined with atorvastatin on acute cerebral infarction. Methods One hundred patients with acute cerebral infarction were randomly divided into observation group （ n = 50 ） and control group （n = 50 ）. The two groups were given conventional therapy. Additionally, the control group was given atorvastatin while the observation group was given monosialotetrahexosyl ganglioside and atorvastatin. Before and after treatment, the levels of serum C-reactive protein （CRP） , interleukin-6 （ IL-6 ）, tumor necrosis factor-c~ （ TNF-ct ）, neuron-specific enolase （ NSE ） and S 100- [5 protein, National Institutes of Health Stroke Scale（NIHSS） score, Activities of Daily Living（ADL） score and clinical efficacy were observed in the two groups. Results After treatment,the levels of serum CRP,IL-6,TNF-c~,NSE and S100-[5,and NIHSS score were lower while ADL score was higher in the observation group compared to those in the control group （P 〈 0.05 ）. The effective rates of the observation group and control group were 84.0% （42/50） and 62.0% （31/50） respectively, the clinical efficacy of the observation group was superior to that of the control group （P 〈 O. 05 ）. Conclusion Monosialotetrahexosyl ganglioside combined with atorvastatin can inhibit local inflammation response and relieve brain injury in the treatment of acute cerebral infarction ,which is superior to atorvastatin therapy alone.